

本會HKBMIA&HKUST DRAP Seminar圓滿舉行！

香港生物醫藥創新協會有限公司

2025-11-07

导读：We are excited to announce that our HKBMIA&HKUST DRAP S

We are excited to announce that our HKBMIA&HKUST DRAP Seminar was successfully held on October 16! The event was led by our President, Professor Lo Yuk Lam, and Dr. Sunny Tam, the Co-Director of Master of Science and Program in Drug Regulatory Affairs and Policy of HKUST (HKUST DRAP).

The seminar began with opening remarks by Prof. Lo Yuk Lam and Dr. Sunny Tam. During the remarks, Prof. Lo highlighted the importance and position of Hong Kong's CMPR (Hong Kong Centre for Medical Products Regulation) in the context of Hong Kong's regulatory modernization and globalization.

Prof. Lo Yuk Lam

"I firmly believe that the future of the CMPR is to become a global benchmark that transcends regional boundaries and is independent and authoritative. It is not just Hong Kong's CMPR, nor merely the regulatory authority for the Guangdong-Hong Kong-Macao Greater Bay Area, and it is not just a regulatory body for China; its future is Asian and global, serving as a beacon of pharmaceutical innovation recognized internationally. Only by establishing such an ambitious goal can the existence of the CMPR be meaningful and truly contribute 'Hong Kong's strength' to the advancement of the global pharmaceutical industry," Prof. Lo said.

Group Photo

During keynote speech session, we invited Dr. Zili Li (Drug Information Association Fellow and Board Member, Former Global Vice President and Head of AP R&D at Johnson & Johnson, and Former Clinical Team Leader and Head of Global Affairs at FDA/CDE) to be the keynote speaker. The topic of his speech was "China Biotech Innovation to Emerging-Market Unmet Needs: Hong Kong as a Catalyst to Build a New Model of Global Collaboration – An Overview of the DIA China Task Force Report."

Dr. Zili Li

After the keynote speech, Dr. Li joined the panel discussion, which was moderated by Dr. Sunny Tam, Co-director of the HKUST DRAP Program. The other two experts, Dr. Antonio Barra Torres (Fellow of the Drug Information Association and Former President-Director of the Brazilian Health Regulatory Agency) and Dr. Liming Zou (DIA Global Talent Development Committee Member and Associate Professor at Westlake University School of Medicine, as well as Former Senior Clinical Reviewer at CDE/NMPA), also participated in the discussion. The topics of the panel discussion centered around Hong Kong's regulatory modernization and reform and the talent needed to realize this vision.